Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab with XELIRI vs XELOX in First-line mCRC
NCT00254137Phase 2Completed
- Sponsor
- Ludwig Maximilian University of Munich
- Start
- Sep 2004
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of cetuximab in metastatic colorectal cancer (mCRC), sponsored by Ludwig Maximilian University of Munich. Started Sep 2004; status: completed.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00254137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00254137.